Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes

Regan, JA; Mentz, RJ; Nguyen, M; Green, JB; Truby, LK; Ilkayeva, O; Newgard, C; Buse, JB; Sourij, H; Sjöström, CD; Sattar, N; McGarrah, RW; Zheng, Y; McGuire, DK; Standl, E; Armstrong, P; Peterson, E; Hernandez, A; Holman, RR; Shah, SH

Journal article

Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes

Abstract:: Metabolic mechanisms underlying the heterogeneity of major adverse cardiovascular (CV) event (MACE) risk in individuals with type 2 diabetes mellitus (T2D) remain unclear. We hypothesized that circulating metabolites reflecting mitochondrial dysfunction predict incident MACE in T2D. Targeted mass-spectrometry profiling of 60 metabolites was performed on baseline plasma samples from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS; discovery cohort) and Exenatide Study of Cardiovascular Event Lowering (EXSCEL; validation cohort) biomarker substudy cohorts. A principal components analysis metabolite factor comprising medium-chain acylcarnitines (MCACs) was associated with MACE in TECOS and validated in EXSCEL, with higher levels associated with higher MACE risk. Meta-analysis showed that long-chain acylcarnitines (LCACs) and dicarboxylacylcarnitines were also associated with MACE. Metabolites remained associated with MACE in multivariate models and favorably changed with exenatide therapy. A third cohort (Cardiac Catheterization Genetics [CATHGEN]) with T2D was assessed to determine whether these metabolites improved discriminative capability of multivariate models for MACE. Nine metabolites (MCACs and LCACs and 1 dicarboxylacylcarnitine) were associated with time to MACE in the CATHGEN cohort. Addition of these metabolites to clinical models minimally improved the discriminative capability for MACE but did significantly down reclassify risk. Thus, metabolites reporting on dysregulated mitochondrial fatty acid oxidation are present in higher levels in individuals with T2D who experience subsequent MACE. These biomarkers may improve CV risk prediction models, be therapy responsive, and highlight emerging risk mechanisms

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Regan, J. A., Mentz, R. J., Nguyen, M., Green, J. B., Truby, L. K., Ilkayeva, O., Newgard, C., Buse, J. B., Sourij, H., Sjöström, C. D., Sattar, N., McGarrah, R. W., Zheng, Y., McGuire, D. K., Standl, E., Armstrong, P., Peterson, E., Hernandez, A., Holman, R. R., & Shah, S. H. (2023). Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. JCI Insight, 8(17), e168563.

MLA Style

Regan, JA, et al. “Mitochondrial Metabolites Predict Adverse Cardiovascular Events in Individuals with Diabetes.” JCI Insight, vol. 8, no. 17, 2023, p. e168563.

Chicago Style

Regan, JA, RJ Mentz, M Nguyen, et al. 2023. “Mitochondrial Metabolites Predict Adverse Cardiovascular Events in Individuals with Diabetes.” JCI Insight 8 (17): e168563.
Print